Laboratory techniques

Molecular Lab Partners LLC Reports 506% Second Quarter Growth Over Prior Quarter

Retrieved on: 
Wednesday, August 4, 2021
Natural sciences, Biotechnology, Molecular biology, Biology, Life sciences, Laboratory techniques, Amplifiers, Polymerase chain reaction, Roche

OVERLAND PARK, Kan., Aug. 4, 2021 /PRNewswire/ -- Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the second quarter of 2021.

Key Points: 
  • OVERLAND PARK, Kan., Aug. 4, 2021 /PRNewswire/ -- Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the second quarter of 2021.
  • The growth is reflective of the strong demand for In-Office PCR Testing Solutions by physicians nationwide.
  • MLP has streamlined a turn-key process that enables physicians to bring molecular PCR based testing in-house with relative ease.
  • Molecular Lab Partners LLC, a privately owned company, specializes in providing hands-on consulting services to physicians interested in bringing molecular based PCR testing in-house as an ancillary service.Their turn-key solution allows physicians to begin operating their own high complexity molecular lab in as little as three months.For additional information about Molecular Lab Partners, please visit molecularlabpartners.com.

OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program

Retrieved on: 
Tuesday, August 3, 2021
Transport in England, Laboratory techniques, Assay, Biochemistry, Titration, A30 road, Transport in the United Kingdom, A30, England

ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program. The A30 RQ analyzers will now proceed into final verification and validation testing.

Key Points: 
  • The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program.
  • Furthermore, the Unyvero A30 RQ platform can be made available to third party development and commercialization partners and licensees for their own assay menu and product portfolio.
  • The Unyvero A30 RQ platform is designed to allow straightforward migration of third party assays using well-established real time PCR technology.
  • This press release includes statements regarding the development of OpGens Unyvero A30 RQ platform.

Applied DNA Awarded The City University of New York (CUNY) COVID-19 Testing Contract

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Education, Continuing, Other Science, University, Research, Infectious diseases, Education, General Health, Science, Branches of biology, Molecular biology, Biology, Articles, Biotechnology, Laboratory techniques, Amplifiers, Polymerase chain reaction, Roche, Applied DNA Sciences, COVID-19 testing, Polymerase, safeCircle™, the Linea™ COVID-19 Assay Kit, Applied DNA Sciences, SAFECIRCLE™, THE LINEA™ COVID-19 ASSAY KIT, APPLIED DNA SCIENCES

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC, (ADCL) was awarded a competitively-bid COVID-19 testing contract by the City University of New York ( CUNY ) Board of Trustees to facilitate the Universitys reopening in the fall (the Contract).

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC, (ADCL) was awarded a competitively-bid COVID-19 testing contract by the City University of New York ( CUNY ) Board of Trustees to facilitate the Universitys reopening in the fall (the Contract).
  • The Contract term is 12 months, has a maximum value not to exceed $35.0 million, and contains no minimum weekly testing commitment.
  • CUNY projects weekly testing in the range of 20,000 to 65,000 tests over the period of the Contract.
  • Testing levels are contingent on vaccination rates, the ratio of in-person versus remote attendance, and positivity rates within the CUNY population.

PCR Molecular Diagnostics Market Research Report 2021 - Global Growth, Trends, COVID-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Health, Other Health, Biotechnology, Branches of biology, Natural sciences, Biology, Laboratory techniques, Molecular biology, Medical tests, Amplifiers, Molecular diagnostics, Polymerase chain reaction

The "PCR Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PCR Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The PCR Molecular Diagnostics market is expected to grow with an estimated CAGR of 3.5%, over the forecast period.
  • Though COVID 19 has a major impact on the medical industry, the PCR Molecular Diagnostics market is on a positive trend.
  • The rising prevalence of cancer and infectious diseases is also a major factor that drives PCR molecular diagnostics market.

The Worldwide Contract Research Organization Services Industry is Expected to Reach $86.5 Billion by 2026

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Quality, Laboratory techniques, Medicine, Cell biology, Clinical pathology, Medical tests, Validation, Cleaning validation, Flow cytometry, Cytometry

6.3.6.1 Increasing Use of Molecular Imaging, Flow Cytometry, and Immunohistochemistry to Boost Segment

Key Points: 
  • 6.3.6.1 Increasing Use of Molecular Imaging, Flow Cytometry, and Immunohistochemistry to Boost Segment
    6.4.6.1 Used to Ensure Long-Term Quality, Safety, and Efficacy of Pharmaceutical Products
    6.4.7.1 Demand for Analytical Method Validation, Cleaning Validation, and Microbial Testing to Propel Segment Growth

TAAG Genetics Secures AOAC Validation for F41 VIP PCR Kit

Retrieved on: 
Monday, August 2, 2021
Natural sciences, Chemistry, Physical sciences, Laboratory techniques, Molecular biology, Biotechnology, Analytical chemistry, Polymerase chain reaction, AOAC International, Real-time polymerase chain reaction, Assay, TAAG Angola Airlines

ST. CHARLES, Ill., Aug. 2, 2021 /PRNewswire/ --TAAG Genetics announced today that its TAAG F41 VIP kit, a multiplex real-time PCR assay capable of detecting four separate foodborne pathogens in a single reaction, has been granted Performance Tested MethodsSM status from the AOAC Research Institute (certification #072101).

Key Points: 
  • ST. CHARLES, Ill., Aug. 2, 2021 /PRNewswire/ --TAAG Genetics announced today that its TAAG F41 VIP kit, a multiplex real-time PCR assay capable of detecting four separate foodborne pathogens in a single reaction, has been granted Performance Tested MethodsSM status from the AOAC Research Institute (certification #072101).
  • As part of that effort, it has developed and validated the F41 VIP, a simple-to-perform method that provides accurate presumptive results in 24 hours from sample enrichment.
  • "We are delighted to have received AOAC validation on the F41 VIP, which is is a crucial step in bringing our international experience in food safety to the US market," said TAAG Genetics' CEO, Denis Berndt.
  • TAAG Genetics is an international laboratory founded in 2001, which has positioned itself on the leading edge of the industry where nature and technology come together.

Delta Variant? There Are Others. Milford Molecular Diagnostics Laboratory Routinely Diagnoses Variants of SARS-CoV-2, Including Alpha, Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa and Lambda Variants

Retrieved on: 
Thursday, July 29, 2021
Health, Infectious diseases, Branches of biology, Biology, Biotechnology, Life sciences, Molecular biology, Laboratory techniques, Polymerase chain reaction, DNA, Molecular diagnostics, DNA sequencing, Reverse transcription polymerase chain reaction

Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.

Key Points: 
  • Sin Hang Lee, director of Milford Molecular Diagnostics, summarizing recently published sequence-based surveillance data.
  • View the full release here: https://www.businesswire.com/news/home/20210729006029/en/
    However, he added, there exists no known diagnostic method for these variants in the U.S. for individual patient samples outside of Milford Diagnostics Laboratory.
  • All variants of concern or of interest must have at least one of these 8 mutated amino acids.
  • Milford Molecular Diagnostics Laboratory is CLIA-certified to perform nested RT-PCR/DNA sequencing for diagnosis of SARS-Co-V-2 and reflex spike protein gene sequencing for variant determination.

A.Menarini Diagnostics launches a new Real Time PCR kit for SARS CoV-2 detection and variant screening, CE marked.

Retrieved on: 
Thursday, July 29, 2021
Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Molecular biology, Polymerase chain reaction, Biotechnology, Amplifiers, Nasopharyngeal swab, Real-time polymerase chain reaction, Severe acute respiratory syndrome coronavirus 2, Assay

FLORENCE, Italy, July 29, 2021 /PRNewswire/ -- Menarini Diagnostics, part of the Menarini Group, announced today the release of a new version of the CoronaMelt Kit launched in November 2020.

Key Points: 
  • FLORENCE, Italy, July 29, 2021 /PRNewswire/ -- Menarini Diagnostics, part of the Menarini Group, announced today the release of a new version of the CoronaMelt Kit launched in November 2020.
  • The second-generation kit, CoronaMelt VAR, will combine SARS CoV-2 viral detection with concurrent genotyping of Alpha, Beta and Gamma variants (formerly known as UK, South African and Brazilian) in an IVD certified diagnostic format validated for use on laboratory Real Time PCR instruments.
  • CoronaMelt VAR is validated for use from oro/nasopharyngeal swabs with the use of standard magnetic bead or column RNA purification solution.
  • The kit is also included in the portfolio of assays that can be fully automated on the Omnia liquid handling series.

Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System

Retrieved on: 
Wednesday, July 28, 2021
Technology, Research, Nanotechnology, Biotechnology, Health, General Health, Other Science, Science, Oncology, Natural sciences, Molecular biology, Laboratory techniques, Branches of biology, Chemistry, Polymerase chain reaction, Amplifiers, Biotechnology, Digital polymerase chain reaction

Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industrys first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today.

Key Points: 
  • Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industrys first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today.
  • This represents a broad portfolio expansion of the Companys original three-color naica system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software.
  • Stilla is offering scientists an opportunity to experience the power and flexibility of 6-color Digital PCR by providing a range of options to drive their evaluations, including both hands-on or remote demonstrations of the naica system.
  • For more information on the Crystal Digital PCR Access Program, email [email protected] or sign up online at: https://www.stillatechnologies.com/6-color-dpcr/ .

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Report 2021-2025: Market is Poised to Grow by $265.55 Million - Increase in Chronic Diseases Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Other Science, Science, Chemistry, Physical sciences, Laboratory techniques, Assay, Biochemistry, Titration, ELISA, ELISA, Branches of biology, Immunology, Enzyme immunoassay, Chlamydia antibodies

The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the enzyme-linked immunosorbent assay (Elisa) testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The enzyme-linked immunosorbent assay (Elisa) testing market analysis includes the end-user segment and geographic landscape.
  • This study identifies the increase in chronic diseases as one of the prime reasons driving the enzyme-linked immunosorbent assay (Elisa) testing market growth during the next few years.